Fadeucravacitinib vs Lomedeucitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Fadeucravacitinib

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Psoriasissmall molecule
Partial signal

NCT06109818 · Phase 2 · completed

The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.

Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)

Result source: NCT06109818

Lomedeucitinib

Developed by Beeline Medicines under a licence from Bristol-Myers Squibb

Phase 2 in Psoriasissmall molecule
Partial signal

NCT05730725 · Phase 2 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.

Reported efficacy

Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)

Result source: NCT05730725

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFadeucravacitinibLomedeucitinib
PASI 75—Trial running · NCT0684219963% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
PASI 90—Trial running · NCT0684219940.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
PASI 100—Trial running · NCT068421993.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
sPGA 0/1—Trial running · NCT0684219955.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
DLQI, change—Trial running · NCT06842199—Not reported

PASI 75

Fadeucravacitinib
—Trial running · NCT06842199
Lomedeucitinib
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

PASI 90

Fadeucravacitinib
—Trial running · NCT06842199
Lomedeucitinib
40.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

PASI 100

Fadeucravacitinib
—Trial running · NCT06842199
Lomedeucitinib
3.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725

sPGA 0/1

Fadeucravacitinib
—Trial running · NCT06842199
Lomedeucitinib
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725

DLQI, change

Fadeucravacitinib
—Trial running · NCT06842199
Lomedeucitinib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fadeucravacitinib
PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved NCT06109818 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fadeucravacitinib: 0 of 4 rows · Lomedeucitinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLomedeucitinib
Dropout rate
7.4%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
3.7%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
—BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
—BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
0%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
acne 14.8% (placebo 0%)
covid-19 11.1% (placebo 0%)
dermatitis acneiform 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
aphthous ulcer 11.1% (placebo 0%)
folliculitis 11.1% (placebo 0%)
upper respiratory tract infection 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
diarrhoea 7.4% (placebo 0%)
headache 7.4% (placebo 0%)
influenza 7.4% (placebo 3.6%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lomedeucitinib

PASI 75 63% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
57.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
72% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
11.5% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
33.3% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
47.8% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.4% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
40% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
sPGA 0/1 55.6% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
69.2% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.2% (n=24) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 50 81.5% (n=27) vs 17.9% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
65.4% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
88.5% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=26) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
34.6% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
85.2% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
73.9% (n=23) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
14.8% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48.1% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
84% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
81.8% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 90 40.7% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
18.5% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
25.9% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13.6% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 100 3.7% (n=27) vs 0% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=26) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=23) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -3.36 vs -0.5 placebo score @ 1wk
absolute change · score
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 14 more results
-6.27 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.05 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.06 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.44 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.95 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.13 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.63 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.66 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.39 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.85 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.16 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.53 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.34 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.55 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fadeucravacitinib's landscape · Lomedeucitinib's landscape